DDInter262 DDInter1376
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Cabozantinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Cabozantinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Epoprostenol
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Cabozantinib may lead to a major life threatening interaction when taken with Epoprostenol
Cabozantinib may lead to a major life threatening interaction when taken with Troleandomycin
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Cabozantinib may lead to a major life threatening interaction when taken with Flurbiprofen